FILTER
BY CATEGORY

View All

COVID-19 Stay Tuned Nutrition For implementers For policymakers Report For researchers Research Urban Health M&E
Emerging Pandemics

Tissue repair strategies: What we have learned from COVID-19 in the application of MSCs therapy

07 Jul 2022

Coronavirus disease 2019 (COVID-19) infection causes a severe proinflammatory storm and lung infection, with more than 200 million confirmed cases and 5 million fatalities worldwide. Over the past two years, a number of vaccinations have been produced to slow the COVID-19 virus's quick spread. Despite this, COVID-19 continues to inflict numerous permanent organ injuries. As a result, cell therapy is receiving a lot of attention in the management of organ damage in this terrible COVID-19 pandemic. Mesenchymal stem cells (MSCs), for instance, have shown promise in COVID-19 patients. Stem cells have been found to be useful in managing COVID-19-induced unfavorable effects by inhibiting cytokine storm and hyperinflammatory syndrome with concurrent tissue regeneration capacity, according to preclinical and clinical data. The data that is now available on the use of stem cells for COVID-19 are discussed in this review.

Download PDF
PUBLISHED BY
Ncbi
YEAR OF PUBLISHING
2022
AUTHORS
Yiran E. Li a , Amir Ajoolabady a , Muralikrishnan Dhanasekaran b, Jun Ren a

Categories

COVID-19
KEY ORGANIZATIONS

FOLLOW US

Disclaimer: This website is made possible by the support of the American People through the United States Agency for International Development (USAID). The Learning4impact partnership is supported by USAID/India Health Office, under Cooperative Agreement # 72038618CA00001 with Swasti. The information provided on this website is not official U.S. Government information and does not necessarily represent the views or positions of USAID, the United States Government, or Swasti.
Copyright 2022 Swasti Health Catalyst